What the FDA labels say about taking them together
Hydrocortisone and lenacapavir
Lenacapavir's FDA label of August 27, 2026 names hydrocortisone in its drug interactions section; the hydrocortisone labels PlainMeds reads (4) do not name lenacapavir. The lenacapavir label: “Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. …”
Check it at the source: the hydrocortisone FDA label on DailyMed (effective August 19, 2026); the lenacapavir FDA label on DailyMed (effective August 27, 2026, Gilead Sciences, Inc.).
What does the hydrocortisone label say about lenacapavir?
Hydrocortisone's label (effective August 19, 2026) and its 3 other brand-application labels do not name lenacapavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (hydrocortisone 1), Kroger Company, effective August 19, 2026 (SPL set f05edff2-2dc5-427c-b52c-518e0aaef4e0), via openFDA; the full label on DailyMed
What does the lenacapavir label say about hydrocortisone?
Lenacapavir label, drug interactionsConcomitant Drug Class/Drug Name: Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone; Effect on Concentration ↑ = Increase, ↓ = Decrease.: ↑ corticosteroids (systemic); Clinical Comment: Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. Initiate with the lowest starting dose and titrate carefully while monitoring for safety.
Source: FDA drug label (Sunlenca), Gilead Sciences, Inc., effective August 27, 2026 (SPL set e5652804-29c4-40d7-aeb2-0142ed2a7b5b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Hydrocortisone | Lenacapavir | |
|---|---|---|
| Labeled for | Osteoarthritis, Asthma, Allergies, Herpes and shingles, Leukemia, lymphoma and myeloma, Crohn's disease and ulcerative colitis, Eczema (atopic dermatitis) | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0613 per gram 1% cream | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once